• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[2 cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide].

作者信息

Okada M, Imamura K, Fuchigami T, Omae T, Iida M, Nanishi F, Murakami M, Ohgushi H, Yao T, Fujita K, Ogawa K

出版信息

Nihon Naika Gakkai Zasshi. 1982 Nov;71(11):1566-72.

PMID:7166673
Abstract
摘要

相似文献

1
[2 cases of nonspecific multiple ulcers of the small intestine associated with osteomalacia caused by long-term intravenous administration of saccharated ferric oxide].[2例长期静脉输注含糖氧化铁致骨软化症合并小肠非特异性多发溃疡]
Nihon Naika Gakkai Zasshi. 1982 Nov;71(11):1566-72.
2
Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia.静脉注射含糖氧化铁诱导的低磷血症：FGF23相关低磷血症的另一种形式。
Bone. 2009 Oct;45(4):814-6. doi: 10.1016/j.bone.2009.06.017. Epub 2009 Jun 23.
3
[Case of osteomalacia due to intravenous saccharated ferric oxide].[静脉注射含糖氧化铁所致骨软化症病例]
Nihon Naika Gakkai Zasshi. 1998 Jul 10;87(7):1372-3.
4
Iatrogenic osteomalacia caused by intravenous administration of saccharated ferric oxide.
Am J Hematol. 1993 May;43(1):75-6. doi: 10.1002/ajh.2830430121.
5
[Case report; A case of FGF23-related hypophosphatemic osteomalacia caused by long-term administration of saccharated ferric oxide].[病例报告；长期服用含糖氧化铁导致的FGF23相关性低磷性骨软化症1例]
Nihon Naika Gakkai Zasshi. 2011 Oct 10;100(10):3031-3. doi: 10.2169/naika.100.3031.
6
Hypophosphatemia induced by intravenous administration of Saccharated iron oxide.
Klin Wochenschr. 1983 Jan 17;61(2):99-102. doi: 10.1007/BF01496662.
7
Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.长期服用含糖氧化铁导致的成纤维细胞生长因子23相关骨软化症
Intern Med. 2012;51(17):2375-8. doi: 10.2169/internalmedicine.51.7450. Epub 2012 Sep 1.
8
[A case of hypophosphatemia induced by intravenous administration of saccharated iron oxide].
Nihon Ronen Igakkai Zasshi. 1994 Oct;31(10):805-10. doi: 10.3143/geriatrics.31.805.
9
[Bone and Nutrition. The relationship between iron and phosphate metabolism].[骨骼与营养。铁与磷代谢之间的关系]
Clin Calcium. 2015 Jul;25(7):1037-42.
10
Administration of intravenous iron sucrose as a 2-minute push to CKD patients: a prospective evaluation of 2,297 injections.对慢性肾脏病患者静脉推注蔗糖铁2分钟：2297次注射的前瞻性评估
Am J Kidney Dis. 2005 Aug;46(2):283-9. doi: 10.1053/j.ajkd.2005.04.032.

引用本文的文献

1
Iron and Bone Pathophysiology.铁与骨的病理生理学
Adv Exp Med Biol. 2025;1480:311-325. doi: 10.1007/978-3-031-92033-2_20.
2
Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials.铁羧基麦芽糖复合物相关的心力衰竭低磷血症风险：临床试验的汇总分析。
ESC Heart Fail. 2023 Apr;10(2):1294-1304. doi: 10.1002/ehf2.14286. Epub 2023 Feb 1.
3
Severe Hypophosphatemia Occurring After Repeated Exposure to a Parenteral Iron Formulation.反复接触一种肠外铁制剂后发生的严重低磷血症。
Case Rep Endocrinol. 2022 Oct 7;2022:1011401. doi: 10.1155/2022/1011401. eCollection 2022.
4
Crosstalk of fibroblast growth factor 23 and anemia-related factors during the development and progression of CKD (Review).慢性肾脏病发生发展过程中，成纤维细胞生长因子23与贫血相关因子的相互作用（综述）
Exp Ther Med. 2021 Oct;22(4):1159. doi: 10.3892/etm.2021.10593. Epub 2021 Aug 11.
5
Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome.静脉铁诱导的低磷血症：一种新兴综合征。
Adv Ther. 2021 Jul;38(7):3531-3549. doi: 10.1007/s12325-021-01770-2. Epub 2021 May 30.
6
Upstream Regulators of Fibroblast Growth Factor 23.成纤维细胞生长因子 23 的上游调节物。
Front Endocrinol (Lausanne). 2021 Feb 26;12:588096. doi: 10.3389/fendo.2021.588096. eCollection 2021.
7
New Therapies for Hypophosphatemia-Related to FGF23 Excess.与 FGF23 过剩相关的低磷血症的新疗法。
Calcif Tissue Int. 2021 Jan;108(1):143-157. doi: 10.1007/s00223-020-00705-3. Epub 2020 Jun 5.
8
Regulation of Fibroblast Growth Factor 23 by Iron, EPO, and HIF.铁、促红细胞生成素和低氧诱导因子对成纤维细胞生长因子23的调节
Curr Mol Biol Rep. 2019 Mar;5(1):8-17. doi: 10.1007/s40610-019-0110-9. Epub 2019 Jan 25.
9
Management of anemia in inflammatory bowel disease: a challenge in everyday clinical practice.炎症性肠病贫血的管理：日常临床实践中的一项挑战。
Prz Gastroenterol. 2017;12(4):239-243. doi: 10.5114/pg.2017.72096. Epub 2017 Dec 14.
10
Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.因使用羧基麦芽糖铁导致的基于成纤维细胞生长因子23的严重低磷性骨软化症。
BMJ Case Rep. 2018 Jan 3;2018:bcr-2017-222851. doi: 10.1136/bcr-2017-222851.